This book by Mike Havrilla and Mark Messier is essentially an infomercial for biorunup.com. While it does have some original content of it's own, I don't think this book is worth much more than $6. Nearly half of the books pages are profiles of biotech companies that were only relevant at the time of the book's release. Thus nearly half of the book is completely worthless.
The value of this book is the explanation of the process in which drugs are approved by the FDA and how that affects the stock price. The process is made clear and the glossary is also well done which makes the book a decent reference for various drug trial events.
While the book offers some interesting strategies, it by no means allows you to perform them using this book alone and instead expects you to buy into their website subscription which I am not a member of so I can't comment on the value of the website. Based on the lack of foresight that went into the making of this book though, I am not interested in trying out their service.
The value of this book is the explanation of the process in which drugs are approved by the FDA and how that affects the stock price. The process is made clear and the glossary is also well done which makes the book a decent reference for various drug trial events.
While the book offers some interesting strategies, it by no means allows you to perform them using this book alone and instead expects you to buy into their website subscription which I am not a member of so I can't comment on the value of the website. Based on the lack of foresight that went into the making of this book though, I am not interested in trying out their service.
No comments:
Post a Comment